T. Rowe Price Associates
IMMX icon

T. Rowe Price Associates’s Immix Biopharma IMMX Stock Holding History

T. Rowe Price Associates’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.78M Buy
+415,001
New +$3.05M ﹤0.01% 1544

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

T. Rowe Price Associates's IMMX Position: Q1 2026 in Review

T. Rowe Price Associates opened a new position in Immix Biopharma (IMMX) in Q1 2026: 415,001 shares worth $3.78M. The stake represents ﹤0.01% of the portfolio and ranks #1544 among its holdings.

77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • T. Rowe Price Associates held 415,001 shares of Immix Biopharma worth $3.78M as of Q1 2026.
  • Immix Biopharma was a new T. Rowe Price Associates position in Q1 2026.
  • Immix Biopharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1544 holding.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.